{"id":199340,"date":"2026-11-05T16:41:52","date_gmt":"2026-11-05T16:41:52","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/199340\/"},"modified":"2026-11-05T16:41:52","modified_gmt":"2026-11-05T16:41:52","slug":"novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons-7","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/199340\/","title":{"rendered":"Novo Nordisk A\/S: Trading in Novo Nordisk shares by board members, executives and associated persons"},"content":{"rendered":"<p>Bagsv\u00e6rd, Denmark. 5 November 2026\u00a0&#8211; This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company\u2019s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596\/2014 on market abuse.<\/p>\n<p>The company\u2019s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf..<\/p>\n<p>Please find below a statement of such trading in shares issued by Novo Nordisk.<\/p>\n<p>Get the latest news<br \/>\n                <br class=\"br-line\"\/><br \/>\n                delivered to your inbox<\/p>\n<p>Sign up for The Manila Times newsletters<\/p>\n<p>            By signing up with an email address, I acknowledge that I have read and agree to the <a href=\"https:\/\/www.manilatimes.net\/terms-of-service\" title=\"Terms of Service\" rel=\"nofollow noopener\" target=\"_blank\">Terms of Service<\/a> and <a href=\"https:\/\/www.manilatimes.net\/privacy-policy\" title=\"Privacy Policy\" rel=\"nofollow noopener\" target=\"_blank\">Privacy Policy<\/a>.<\/p>\n<p>1 Details of the person discharging managerial responsibilities\/person closely associated a)Name of the Board member\/Executive\/Associated PersonMartin Holst Lange\u00a02 Reason for the notification\u00a0a)Position\/statusExecutive Vice President, R&amp;D and Chief Scientific Officer (CSO)\u00a0b)Initial notification\/AmendmentInitial notification\u00a03 Details of the issuer\u00a0a)NameNovo Nordisk A\/S\u00a0b)LEI549300DAQ1CVT6CXN342\u00a04 Details of the transaction(s)\u00a0a)Description of the financial instrument,<\/p>\n<p>type of instrument,<\/p>\n<p>Shares\u00a0\u00a0Identification codeNovo Nordisk B DK0062498333\u00a0b)Nature of the transactionSale of shares\u00a0c)Price(s) and volume(s)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Price(s)Volume(s)\u00a0\u00a0\u00a0DKK 285.0012,000\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0d)Aggregated information <\/p>\n<p>12,000<\/p>\n<p>DKK 3,420,000.00<\/p>\n<p>\u00a0e)Date of the transaction2026-11-04\u00a0f)Place of the transactionNasdaq Copenhagen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>Novo is the global healthcare company that believes lasting health starts now. For over a century, we\u2019ve combined leading scientific expertise with a deep understanding of people\u2019s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we\u2019re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk&#8217;s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E3J9sAgL9J4UYCTPTkOyjrgP-3Yu1h-xMIydTqHo1raKVSMBc21BeWdgXvAlK1c6Y5I3UMeDAVNpKEgPOUN24V1qymcjaSfPCAMSQFut4LQ=\" rel=\"nofollow noopener\" target=\"_blank\">novonordisk.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jwuU7CF_sqERNqP8IeE-Sr1Ah1rYrY3UoxQ7SlGsEPzShRpI4btQcNWx7TycR6XVLAu4p7pJpYW9IypHUKsNJxY79zlZCXpMCgZQ98PRoMY=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zoDwHh6LMKzcG2UZkbFh78TCmSOJxeqaC8hjkpJG-WdCP-UmOgz2b6_gdV7iDwnr5bS6m39Raq63-CZ7VorlKabyc3rGGSIKOJHoehdkA7Q5jbV_7SOWVgxgODJG4LYU\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XzCgLZq33JbPXAqIMHp-LtSREO5m7BHIhnQzMjHfjQksitRWgGbL4gU39Ksxo_5xfWcT9RD-cZO4CsVnqSiELkcDb-BCoOK-3Xlu_-Q9lh0=\" rel=\"nofollow noopener\" target=\"_blank\">TikTok<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5_mtkrPbhK90XdA8YhlT4T5Hd1c70-nCY4llBJG2SxklkZAwnJfWjQJnygB475oAW6RbSq5qJaVTLNZiizO8eY1ZIqvgoq2EVu_Iahjf2is=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QKsXXLG2mR2qQDI9KLG-TE6wr1TNJV65eilA57Z485HycuoEqSHE4wjrEYwCeCjQ5zDCeuKlrxC7yrBVHuw5hA==\" rel=\"nofollow noopener\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-ku2jyKaT2MwNe1e7EVVfX8LgJIATiRZEYHsOlSx9AOHPGKJ1imZjWxleKY3LPQ9YzoMmN-36R8qBizWXa5NqFYIF9pBNPwk71m6j2zmsDs=\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.\u00a0<\/p>\n<p>Contacts for further information<\/p>\n<p>  Company announcement No 66 \/ 2026<\/p>\n<p>Attachment<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ioahapMuanm-V4xkKOcGaQ0G_H2NAvVmqdVvA2On1PD-o9lTD329OUv8Z8DZjYcufIzAKzyv1pbU7DsZ20oU25ZW7LpRQkHZWaR8HlDbMfMXNWBG1I4OtVoz6dthF-NBYPw08BIIhc1QeIub2ZNPUZxcZo3njcGFZfoZLERgEmROjlrcN3rlbWYpOQDesHywvpdEVcND4zGWnSqYJJe2XQ==\" rel=\"nofollow noopener\">261105_PDMR trading_MartinHolstLange<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/1793896912_512_Novo-Nordisk-A-S.png\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Bagsv\u00e6rd, Denmark. 5 November 2026\u00a0&#8211; This company announcement discloses the data of the transaction(s) made in Novo Nordisk&hellip;\n","protected":false},"author":2,"featured_media":199341,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1128,141,6748,6004,1312,6747,216,5349,5691,3845,272,1313,512,6746],"class_list":["post-199340","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-a-s","tag-and","tag-associated","tag-board","tag-by","tag-executives","tag-in","tag-members","tag-nordisk","tag-novo","tag-novo-nordisk","tag-persons","tag-shares","tag-trading"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117564836896641099","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/199340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=199340"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/199340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/199341"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=199340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=199340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=199340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}